Lv5
893 积分 2022-10-12 加入
Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
4天前
已完结
Impact of thyroid disorders on flow-mediated dilation: a systematic review and meta-analysis
5天前
已完结
Nailfold Capillaroscopy in Hypothyroidism and Hyperthyroidism: Blood Flow Velocity During Rest and Postocclusive Reactive Hyperemia
5天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
9天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
9天前
已完结
Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
10天前
已完结
British Association of Dermatologists guidelines for the management of people with vitiligo 2021
12天前
已完结
Case Series: Effectiveness and Safety of Telitacicept in Chinese Patients With Primary Sjögren's Disease
16天前
已完结
Treatment of bone metastases before the onset of pain
17天前
已完结
"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study
25天前
已关闭
皖公网安备34019202002308
